Tirzepatide

Weight Loss · Metabolism Subcutaneous Injectable (Weekly)

Tirzepatide is currently the most effective medication available for weight loss and metabolic restoration. Its dual receptor activity on both GLP-1 and GIP pathways produces significant improvements in appetite regulation, insulin sensitivity, and cardiometabolic markers — typically with greater magnitude than GLP-1-only options.

Best for: Meaningful weight loss goals, insulin resistance, metabolic syndrome, pre-diabetes.

Book Consult→ Get discounts with memberships →

Frequently Asked

What clients want to know about Tirzepatide

The questions, answered.

Significant weight loss — often 15–25% of body weight over 12 months.
Improves insulin sensitivity and glucose control.
Reduces visceral fat alongside subcutaneous fat.
Cardiometabolic markers improve — lipids, blood pressure, A1C.
Reduces food noise and cravings.
Sustainable hunger regulation as long as dosed.

GLP-1 receptor agonism: slows gastric emptying, increases satiety, improves insulin secretion.
GIP receptor agonism: enhances insulin sensitivity and fat metabolism.
Central appetite regulation: reduces hypothalamic hunger signaling.
Reduced reward-driven eating via brain receptor crossover.

Weeks 1–2: Nausea acclimation; appetite reduction kicks in; early weight loss begins.
Weeks 4–6: Steady weight loss; food noise quiets; energy stabilizes.
Weeks 8–12: Substantial weight and metabolic gains; titration to maintenance dose discussed.

Nausea, especially early — typically resolves with titration.
Constipation or diarrhea.
Fatigue during the first 1–2 weeks.
Injection-site reactions.
Gallbladder symptoms in some clients during rapid weight loss.

Eat small protein-rich meals rather than large ones to manage nausea.
Hydrate aggressively — 80+ oz of water daily.
Add fiber and electrolytes to manage GI symptoms.
Strength train — preserves muscle mass during weight loss.
Don't skip protein — aim for 1g per pound of target body weight.

Personal or family history of medullary thyroid carcinoma or MEN-2 syndrome.
Active pancreatitis or history of pancreatic disease.
Pregnancy or breastfeeding.
Severe gastrointestinal disease including gastroparesis.

Important Note The FDA's position on peptides continues to evolve. Availability of specific compounds may change, and not all peptides discussed are currently offered at every visit. Book a consultation with our provider team to discuss your goals, current options, and what's appropriate for you.

Tirzepatide

The questions, answered.

Layered with intention.

Precision protocols.
Designed around you.

Tirzepatide

The questions, answered.

Layered with intention.

Precision protocols.Designed around you.

Precision protocols.
Designed around you.